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Background. Although thrombolytic therapy has been shown to be beneﬁcial to stroke patients, the eﬀectiveness of intravenous
thrombolysis in ischemic stroke patients with ventricle myxoma is unknown. Case Description. A 22-year-old woman with left
hemiplegia was sent to the emergency department at a teaching hospital. The magnetic resonance angiography showed occlusion
of the right middle cerebral artery, and the echocardiography showed a mass in the left ventricle. Intravenous recombined tissue
plasminogen activator (rt-PA) was administrated, and the postthrombolysis transcranial Doppler exam showed that her right
middle cerebral artery was circulative. The patient’s condition improved gradually, and no complication was observed up to 16
months of follow-up. Conclusion. Intravenous rt-PA is a reasonable treatment for stroke patients with ventricle myxoma.
1.Introduction
Myxomarepresents50%ofprimary cardiactumors.Embolic
stroke is the most common neurological manifestation of
cardiac myxoma [1, 2], but the role of thrombolytic therapy
in the treatment of stroke patients with cardiac myxoma
is unknown. Considering that thrombolytic therapy has a
3-hour time-window only, physicians seldom performed a
completecardiac evaluationwhen applying thethrombolytic
therapy to stroke patients. We hereby report a patient
with left ventricle myxoma who received an intravenous
recombined tissue plasminogen activator (rt-PA) treatment
and showed gradual symptom improvement without com-
plications up to 16 months of followup.
2.CaseReport
The patient was a 22-year-old, 53Kg, right-handed woman
with a history of exertional dyspnea who had suﬀered from
three episodes of syncope. There was no family history of
stroke.She had no history of headache, smoking, or drinking
and no history of taking birth control pills. She suddenly
developed left-side limbs weakness and was brought to the
emergency department at a teaching hospital within one
hour of stroke onset. At the emergency department, her
blood pressure was 104/68mmHg, and she had a regular
heart rateof72 with normal heart sounds. Shewas conscious
and well oriented. Her eyes were deviated to the right side,
and her right eye vision was lost. She had a severe left-
side hemiparesis and a left central type facial palsy. Her
NationalInstitutesofHealth-Stroke-Scale(NIHSS)scorewas
12, and her modiﬁed rankin score (mRS) was 4. Results
of her hematologic and biochemistry tests were normal,
and her chest roentgenogram revealed a normal heart
size. The brain computerized tomography (CT) showed no
abnormaldensity,andtheelectrocardiogram (ECG)revealed
sinus rhythm. There was no carotid bruit. Intravenous
administration of rt-PA (0.9mg/Kg) was given between 125
to 185min after the stroke onset.
On the next day, her blood sugar, cholesterol, triglyc-
eride, protein C, protein S, antithrombin, antinuclear anti-
body, anticardiolipin, and homocystein values were normal.2 Stroke Research and Treatment
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Figure 1: Transthoracic echocardiogram from apical 4-chamber
view showed one myxoma (arrow) in the left ventricle with
diameter 3 ×4cm and stalk on middle interventricular septum.
Figure 2: MRI of brain shows infarct in right putamen and tempo-
ral lobe (arrows).
A neurological examination showed a mild improvement,
w i t hN I H S So f1 1a n dm R So f4 ,b u tn oc h a n g ei nm u s c l e
power or facial palsy. Her transthoracic echocardiogram
revealed a large (3 × 4cm) homogenous mass with a stalk
attached to the left interventricular septum (Figure 1), but
her carotid duplex ultrasonography was normal. A transcra-
nial Doppler (TCD) exam showed a decrease in blood ﬂow
in the right middle cerebral artery. From T2 and diﬀusion-
weighted magnetic resonance image (MRI), infarcts in right
basal ganglion and temporal lobe were observed (Figure 2).
Figure 3:MRAshowsrightproximalmiddlecerebral artery(MCA)
occlusion (arrow).
Figure 4: Sixteen months after thrombolytic therapy, MRA shows
right middle cerebral artery recanalization (arrow).
Magnetic resonance angiography (MRA) showed occlusion
of the right middle cerebral artery in the proximal section
(Figure 3). No adverse eﬀects following the thrombolytic
therapy were observed.
The patient received a tumor resection, and the patho-
logical examination conﬁrmed the diagnosis of left ventricle
myxoma. The postoperation clinical course was uneventful
without further syncope episodes. Her neurological symp-
toms improved gradually, but her visual acuity had no
improvement. Ten months after the thrombolytic therapy,Stroke Research and Treatment 3
her NIHSS was 5 and mRS was 2. Sixteen months after
the therapy, the MRA showed right middle cerebral artery
recanalization (Figure 4).
3.Discussion
Approximately 75% of cardiac myxomas are located in
the left atrium, and only 2.5% of them occur in the left
ventricle [3, 4] Clinical manifestations of cardiac myxoma
include constitutional, obstructive, and embolic symptoms.
Constitutional symptoms (recurrent fever, malagia, and
weight loss) occur in 34 to 90% of patients, and obstructive
symptoms (fatigue, weakness, dyspnea, and syncope) occur
in 54 to 95% of patients. Embolic symptoms were reported
in 10 to 45% of cases [2]. Neurological symptoms present
in 12 to 45% of patients, and embolic cerebral infarct is the
most common event [1, 5].
Thrombolysis with intravenous rt-PA treatment within
three hours of ischemic stroke is now widely applied
because it has been found to be beneﬁcial to patient’s
outcome. In this patient, acute occlusions of the right
middle cerebral artery and retinal artery were likely to
be caused by embolism from the left ventricle myxoma.
This patient had received a complete dose of rt-PA before
her myxoma was diagnosed by transthoracic echocardio-
graphy. After the thrombolytic therapy, the patient’s neu-
rological symptoms improved. Although MRA did not
show recanalization of the right middle cerebral artery,
TCD showed that the right middle cerebral artery was
circulative. Approximately 41% of cardiac myxomas have
surface emboli, and systemic embolization related to myx-
oma surface thrombus is most likely [5]. Because cases of
embolicstrokefollowing thrombolytictherapyofmyocardial
infarction were reported [6], cardiac myxoma was once
considered as a contraindication for thrombolytic ther-
apy, but such an argument has not been well established
[7].
Successful thrombolytic therapy with rt-PA in acute
ischemic stroke patients with cardiac thrombus has been
reported [8, 9], and intra-arterial thrombolysis of cerebral
artery occlusionwith urokinase has beendemonstrated to be
capable of causing partial recannalization [10]. However, a
previousreportshowedthatthrombolytictherapyinpatients
with ventricular thrombous may cause embolic stroke [6].
The response to intravenous thrombolysis by myxomatous
embolic stroke patients is unpredictable.
Using “ventricular myxoma,” “thrombolytic therapy,”
“stroke,” and “cerebrovascular disease” as key words, we
d i dn o tﬁ n da n yr e p o r t so ns i m i l a rc a s e si nt h eP u b M e d
databases. Intravenous thrombolytic therapy in acute is-
chemic stroke patients, caused by left atrial myxoma, had
been reported to be an eﬀective treatment [11]. However,
thrombolytic therapy in patients caused by ventricular
myxoma has not beenreported. Therefore, the case described
in this paper is probably the ﬁrst reported evidence of a
successful thrombolytic therapy in a stroke patient with
presumed left ventricular myxomatous embolism. Based on
this case, thrombolytic therapy with IV rt-PA is reasonable
for ischemic stroke patients with ventricular myxoma.
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